Deep in talks with J&J, Actelion’s flagship drug cruises past a pivotal trial failure
Deep into negotiations with J&J over a prospective buyout, Actelion (SIX: ATLN) reported today that its up-and-coming flagship therapy Opsumit flunked a pivotal test for treating pulmonary arterial hypertension due to Eisenmenger Syndrome. And while the trial failure could put a crimp in Actelion’s — as well as J&J’s — plan to continue to rapidly boost sales of Opsumit as Tracleer loses ground to generic competition, analysts seemed ready to write it off and move on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.